How can patient preferences be used and communicated in the regulatory evaluation of medicinal products? Findings and recommendations from IMI PREFER and call to action

How can patient preferences be used and communicated in the regulatory evaluation of medicinal products? Findings and recommendations from IMI PREFER and call to action

Objective: Patients have unique insights and are (in-)directly affected by each decision taken throughout the life cycle of medicinal products. Patient preference studies (PPS) assess what matters most to patients, how much, and what trade-offs patients are willing to make. IMI PREFER was a six-year...

Full description

Bibliographic Details
Main Authors: Rosanne Janssens, Liese Barbier, Mireille Muller, Irina Cleemput, Isabelle Stoeckert, Chiara Whichello, Bennett Levitan, Tarek A. Hammad, Charis Girvalaki, Juan-Jose Ventura, Karin Schölin Bywall, Cathy Anne Pinto, Elise Schoefs, Eva G. Katz, Ulrik Kihlbom, Isabelle Huys
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Pharmacology
Subjects:
patient preferences
patient experience data
regulatory evaluation
scientific advice
benefit-risk assessment
clinical trial endpoint selection
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1192770/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1192770/full

Similar Items